Carmine Pinto

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Oncol 18:510-7. 2007
  2. ncbi Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1)
    Carmine Pinto
    Unit of Medical Oncology, S Orsola Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy
    Lung Cancer 52:199-206. 2006
  3. ncbi 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
    Chiara Funaioli
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Tumori 93:611-5. 2007
  4. ncbi The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab
    Francesca Di Fabio
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni, 15 40138, Bologna, Italy
    Gastric Cancer 10:221-7. 2007
  5. ncbi Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
    Raffaele Lombardi
    General Surgery Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Surg Oncol 17:838-45. 2010
  6. ncbi Multimodal sequential approach in colorectal cancer liver metastases: hepatic resection after yttrium-90 selective internal radiation therapy and cetuximab rescue treatment
    Sara Pini
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Tumori 96:157-9. 2010
  7. ncbi Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Rome, Italy
    Expert Opin Biol Ther 9:945-9. 2009
  8. ncbi Treatment of advanced gastric cancer with cetuximab plus chemotherapy followed by surgery. Report of a case
    Riccardo Casadei
    Dipartimento Emergenza Urgenza, Chirurgia Generale e dei Trapianti, Alma Mater Studiorum, Universita degli Studi di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Tumori 95:811-4. 2009
  9. ncbi Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial)
    Andrea Angelo Martoni
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy
    Eur J Cancer 42:3161-8. 2006
  10. ncbi Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
    C Pinto
    Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Br J Cancer 101:1261-8. 2009

Collaborators

Detail Information

Publications17

  1. ncbi Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Oncol 18:510-7. 2007
    ..The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma...
  2. ncbi Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1)
    Carmine Pinto
    Unit of Medical Oncology, S Orsola Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy
    Lung Cancer 52:199-206. 2006
    ....
  3. ncbi 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
    Chiara Funaioli
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Tumori 93:611-5. 2007
    ..New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents...
  4. ncbi The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab
    Francesca Di Fabio
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni, 15 40138, Bologna, Italy
    Gastric Cancer 10:221-7. 2007
    ....
  5. ncbi Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
    Raffaele Lombardi
    General Surgery Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Surg Oncol 17:838-45. 2010
    ..We analyzed a group of patients with cT3N0 low rectal cancer who underwent neoadjuvant chemoradiotherapy with the purpose of evaluating the incidence of metastatic nodes in the resected specimens...
  6. ncbi Multimodal sequential approach in colorectal cancer liver metastases: hepatic resection after yttrium-90 selective internal radiation therapy and cetuximab rescue treatment
    Sara Pini
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Tumori 96:157-9. 2010
    ..We present a case in which such an approach was put into practice. The favorable result suggests that SIRT, along with systemic chemotherapy and surgery, is a valid treatment option for unresectable colorectal liver metastases...
  7. ncbi Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Rome, Italy
    Expert Opin Biol Ther 9:945-9. 2009
    ..The aim of this study was to evaluate the effect of cigarette smoking on cetuximab efficacy in advanced colorectal cancer patients...
  8. ncbi Treatment of advanced gastric cancer with cetuximab plus chemotherapy followed by surgery. Report of a case
    Riccardo Casadei
    Dipartimento Emergenza Urgenza, Chirurgia Generale e dei Trapianti, Alma Mater Studiorum, Universita degli Studi di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Tumori 95:811-4. 2009
    ..The patient is alive, well and disease-free ten months after surgery. The good result achieved in this patient provides interesting prospects for chemotherapy combined with cetuximab, followed by surgery...
  9. ncbi Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial)
    Andrea Angelo Martoni
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy
    Eur J Cancer 42:3161-8. 2006
    ..This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)...
  10. ncbi Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
    C Pinto
    Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Br J Cancer 101:1261-8. 2009
    ..The purpose of this phase II study was to evaluate the activity and safety of cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma...
  11. ncbi Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy
    Carmine Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy
    Oncologist 16:228-38. 2011
    ..Appropriate management of skin toxicity associated with epidermal growth factor receptor inhibitor (EGFR-i) therapy is necessary to allow adequate drug administration and to improve quality of life and outcomes...
  12. ncbi Role of 18F-FDG PET for evaluating malignant pleural mesothelioma
    Cristina Nanni
    , Bologna, Italy
    Cancer Biother Radiopharm 19:149-54. 2004
    ..In conclusion, FDG PET was found to play a worth-while role in patient management...
  13. ncbi Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma
    A Martoni
    Department of Oncology and Haematology, S. Orsola-Malpighi Hospital, Bologna, Italy
    Ann Oncol 12:519-24. 2001
    ....
  14. ncbi Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma
    Carmine Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy
    Am J Clin Oncol 34:99-109. 2011
    ..This Consensus did not answer all of the unresolved questions in MPM management, but the Expert Opinions have nonetheless provided recommendations, presented in this report, on MPM management for clinicians and patients...
  15. ncbi Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?
    Chiara Funaioli
    Medical Oncology Unit, Policlinico Sant Orsola Malpighi, Bologna, Italy
    Clin Colorectal Cancer 6:38-45. 2006
    ..The only biomarker likely to have a prognostic value is microsatellite instability status, which correlated with a better prognosis...
  16. ncbi Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study
    A Martoni
    U O di Oncologia Medica, Dipartimento di Oncologia e Ematologia, Policlinico S Orsola Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    Anticancer Res 23:687-91. 2003
    ..The reasons for the low activity observed could at least in part be related to a reduction in the RTX dose intensity...
  17. ncbi Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study
    C Pinto
    Division of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Am J Clin Oncol 24:143-7. 2001
    ..8%, 13.6%, and 22.7% of patients, respectively. From the data presented here, this regimen can be considered active in the treatment of malignant pleural mesothelioma...